English  |  正體中文  |  简体中文  |  Total items :2828138  
Visitors :  32087794    Online Users :  1454
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"schellens j h m"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 1-4 of 4  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-09-15T01:08:59Z A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors Naing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; Chia-Chi Lin; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M.
臺大學術典藏 2022-08-19T00:20:33Z Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYnote-028 study ?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; CHIUN HSU; Le Tourneau C.; Hollebecque A.
臺大學術典藏 2021-02-18T01:45:22Z Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study Mehnert J.M.;Bergsland E.;O??Neil B.H.;Santoro A.;Schellens J.H.M.;Cohen R.B.;Doi T.;Ott P.A.;Pishvaian M.J.;Puzanov I.;Aung K.L.;Chiun Hsu;Le Tourneau C.;Hollebecque A.;?Lez E.;Tamura K.;Gould M.;Yang P.;Stein K.;Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; Chiun Hsu; Le Tourneau C.; Hollebecque A.; ?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A.
臺大學術典藏 2020-05-25T07:35:01Z A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors Naing A; Gainor J.F; Gelderblom H; Forde P.M; Butler M.O; Chia-Chi Lin; Sharma S; Ochoa De Olza M; Varga A; Taylor M; Schellens J.H.M; Wu H; Sun H; Silva A.P; Faris J; Mataraza J; Cameron S; Bauer T.M.

Showing items 1-4 of 4  (1 Page(s) Totally)
1 
View [10|25|50] records per page